Roquinimex

Roquinimex

Clinical data
ATC code	L03AX02 (WHO)
Pharmacokinetic data
Elimination half-life	26-42 hours
Identifiers
IUPAC name 4-hydroxy-N,1-dimethyl-2-oxo-N- phenyl-1,2-dihydroquinoline-3-carboxamide
CAS Number	84088-42-6 Y
PubChem CID	55197
ChemSpider	10619239 N
UNII	372T2944C0
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H16N2O3
Molar mass	308.331 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C2=CC=CC=C2C(=C(C1=O)C(=O)N(C)C3=CC=CC=C3)O
InChI InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3 N Key:SGOOQMRIPALTEL-UHFFFAOYSA-N N
NY (what is this?)  (verify)

WikiDoc Resources for Roquinimex
Articles
Most recent articles on Roquinimex Most cited articles on Roquinimex Review articles on Roquinimex Articles on Roquinimex in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Roquinimex Images of Roquinimex Photos of Roquinimex Podcasts & MP3s on Roquinimex Videos on Roquinimex
Evidence Based Medicine
Cochrane Collaboration on Roquinimex Bandolier on Roquinimex TRIP on Roquinimex
Clinical Trials
Ongoing Trials on Roquinimex at Clinical Trials.gov Trial results on Roquinimex Clinical Trials on Roquinimex at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Roquinimex NICE Guidance on Roquinimex NHS PRODIGY Guidance FDA on Roquinimex CDC on Roquinimex
Books
Books on Roquinimex
News
Roquinimex in the news Be alerted to news on Roquinimex News trends on Roquinimex
Commentary
Blogs on Roquinimex
Definitions
Definitions of Roquinimex
Patient Resources / Community
Patient resources on Roquinimex Discussion groups on Roquinimex Patient Handouts on Roquinimex Directions to Hospitals Treating Roquinimex Risk calculators and risk factors for Roquinimex
Healthcare Provider Resources
Symptoms of Roquinimex Causes & Risk Factors for Roquinimex Diagnostic studies for Roquinimex Treatment of Roquinimex
Continuing Medical Education (CME)
CME Programs on Roquinimex
International
Roquinimex en Espanol Roquinimex en Francais
Business
Roquinimex in the Marketplace Patents on Roquinimex
Experimental / Informatics
List of terms related to Roquinimex

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.

Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.